Trial | NCT00426296  Report issue

Title

SHARE: Simple HAART With Abacavir, Reyataz, and Epivir
An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    None
SHARE: Simple HAART with Abacavir, Reyataz, and Epivir
Open-label, multicenter study of ABC/3TC + ATV in subjects who have completed at least 24 weeks of treatment on ABC/3TC+ATV/RTV as their first line regimen and have plasma HIV-1 RNA <50 copies/mL at entry
Study Started
Aug 31
2006
Last Update
Nov 01
2007
Estimate

Drug atazanavir (Reyataz)

Drug ritonavir (Norvir)

Criteria 

Inclusion Criteria:

Currently taking abacavir/lamivudine (Epzicom) in combination with atazanavir (Reyataz) boosted with ritonavir (Norvir) as first antiretroviral regimen
Viral load <50 copies/ml

Exclusion Criteria:

Viral load >50 copies/ml
Having taken more than one antiretroviral regimen
No Results Posted